SecurityGTIM / Good Times Restaurants, Inc. (382140879)
President, CEOHOBACK BOYD E
IndustryRestaurants, Dining, and Eating Places
Institutional Owners19
Institutional Shares3,471,105 - 27.84%
Common Shares Outstanding12,468,326 shares (as of 2018-03-27)
Institutional Value$ 10,039,000 USD

Institutional Stock Ownership and Shareholders()

Good Times Restaurants, Inc. (NASDAQ:GTIM) has 19 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 3,471,105 shares. Largest shareholders include Delta Partners Llc, Manatuck Hill Partners, LLC, Granite Point Capital Management, L.P., Vanguard Group Inc, Renaissance Technologies LLC, BlackRock Inc., Geode Capital Management, Llc, Wall Street Associates, Deutsche Bank Ag\, and Macquarie Group Ltd.
Good Times Restaurants, Inc. (NASDAQ:GTIM) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-02-14 13F-HR DELTA PARTNERS LLC 2,271,226 1,392,109 -38.71 6,132 3,689 -39.84
2018-05-10 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 15,000 15,000 0.00 40 46 15.00
2018-05-09 13F-HR BlackRock Inc. 67,669 67,052 -0.91 179 205 14.53
2018-05-15 13F-HR Granite Point Capital Management, L.P. 273,050 273,050 0.00 724 833 15.06
2018-05-14 13F-HR MORGAN STANLEY 14,000 14,023 0.16 37 43 16.22
2018-05-11 13F-HR DIMENSIONAL FUND ADVISORS LP 16,162 49
2018-05-14 13F-HR Virtu Financial LLC 17,277 0 -100.00 46 0 -100.00
2017-02-10 13F-HR BlackRock Fund Advisors 33,271 34,123 2.56 112 107 -4.46
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 9 0 -100.00 0 0
2018-04-12 13F-HR ACADIAN ASSET MANAGEMENT LLC 1,092 0 -100.00 3 0 -100.00
2018-04-24 13F-HR Baystate Wealth Management LLC 300 0 -100.00 1 0 -100.00
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 56,983 56,983 0.00 151 173 14.57
2018-05-15 13F-HR DEUTSCHE BANK AG\ 43,342 45,755 5.57 114 139 21.93
2018-05-15 13F-HR UBS Group AG 903 1,420 57.25 2 4 100.00
2018-05-15 13F-HR TWO SIGMA SECURITIES, LLC 16,274 0 -100.00 43 0 -100.00
2017-02-09 SC 13G/A Wellington Trust Company, National Association Multiple Common Trust Funds Trust, Micro Cap Equity Portfolio 614,500 0 -100.00 0 -100.00
2018-05-15 13F-HR Manatuck Hill Partners, LLC 1,041,400 1,041,400 0.00 2,760 3,176 15.07
2017-01-18 13F-HR WALL STREET ASSOCIATES 51,900 51,900 0.00 175 163 -6.86
2018-05-11 13F-HR MACQUARIE GROUP LTD 37,861 36,461 -3.70 100 111 11.00
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 25,936 25,936 0.00 87 82 -5.75
2018-05-15 13F-HR VANGUARD GROUP INC 232,022 256,374 10.50 615 782 27.15
2017-02-10 13F-HR BlackRock Investment Management, LLC 1,900 1,900 0.00 6 6 0.00
2018-05-14 13F-HR Renaissance Technologies LLC 74,700 106,000 41.90 198 323 63.13
2018-05-03 13F-HR BUCKHEAD CAPITAL MANAGEMENT LLC 17,600 12,700 -27.84 47 39 -17.02
2018-05-09 13F-HR NORTHERN TRUST CORP 22,757 22,757 0.00 60 69 15.00

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Related News Stories

Top Ranked Momentum Stocks to Buy for June 22nd

14h zacks
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 22nd: (52-0)

Good Times Restaurants Is Just Not Profitable

2018-06-05 seekingalpha
GTIM operates Good Times Burgers and Frozen Custard as well as Bad Daddy's. Bad Daddy's, in particular, has some excellent reviews, and stores look like they're busy. That's good. (1-0)

Good Times Restaurants' (GTIM) CEO Boyd Hoback on Q1 2018 Results - Earnings Call Transcript

2018-05-13 seekingalpha
Good Times Restaurants Inc. (NASDAQ:GTIM) Q1 2018 Earnings Conference Call May 10, 2018 5:00 PM ET (1-0)

Restaurant Stocks Hurt by High Costs, Low Traffic

2018-04-04 zacks
The restaurant industry has been troubled by soft consumer spending environment over the past few quarters. Although the current economic backdrop is favorable with rise in in wages, jobless claims at a record low and upbeat consumer confidence, the benefits have not trickled down to the restaurant space yet. (75-0)

CUSIP: 382140879